Filing Flows › Companies › Whitehawk Therapeutics › Report card
Whitehawk Therapeutics earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate2 of 4 reports beat the EPS estimate
Whitehawk Therapeutics (WHWK) beat the analysts' EPS estimate in 2 of its last 4 reports (50%), by -4.1% on average. Next report: Nov 9, 2026, analysts expect EPS −$0.24.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | GAAP EPS |
|---|---|---|---|---|---|
| Q to Jun 2026 | Aug 6, 2026 | −$0.26 | −$0.20 | +23.1% | −$0.20 |
| Q to Mar 2026 | May 7, 2026 | −$0.33 | −$0.32 | +2.0% | −$0.32 |
| Q to Dec 2025 | Mar 12, 2026 | −$0.27 | −$0.34 | -25.9% | — |
| Q to Sep 2025 | Nov 6, 2025 | −$0.22 | −$0.25 | -15.4% | −$0.26 |
Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Whitehawk Therapeutics: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.